A white "Biointelect" logo is displayed against a dark green/black background.
Search
Contact Us
Home › Company › Our People

Our People

With a robust understanding of the life science ecosystem, our Biointelect team possess decades of experience working across a multitude of innovative health projects.

Our Board

Jennifer Herz, Co-founder of Biointelect
Jennifer Herz

Co-founder & Director

Karl Herz, Co-founder of Biointelect
Karl Herz

Co-founder

Our Leadership Team

Leah Goodman, Biointelect's Chief Executive Officer
Leah Goodman

Chief Executive Officer

Dr Patricia Vietheer

Senior Director, R&D Strategy & Planning

Brian Gilmartin

Director, Regulatory Affairs

Katrina Lapham

Director, Strategic Market Access & Policy

Nicola Richards

Director, Strategic Market Access & Policy (Interim)

Jacqui Wade

Director, Clinical Affairs & Director Services

Our Team

Dr Danijela Mirosa

Senior Consultant Manager, Business Development Head

Dr Gary O'Brien

Senior Health Economics and Market Access Manager

Sophie Goddard

Manager Consultant 

Dr Jacky Arkell

Senior Consultant – Regulatory Affairs

Dr Clare Fedele

Senior Consultant – R&D Strategy and Planning

Lena Miloradovic

Strategic Project Manager

Kara Gooley

Senior Project Manager – Clinical Affairs

Nathan Fox

Health Economics Lead

Dr Alysha Elliott

Project Manager – Clinical Affairs

Dr Audrey Rollin

Consultant

Nicole Murray

Senior Associate

Vincent Victory

Senior Associate

Athiya Azeem

Associate

Jasmine Perera

Business Insights Associate

Nicki Sidwell

Executive Officer and Marketing Associate

Marcelo Salvatte Pinheiro

Quality Lead

Senior Analyst and Operations Support professional at Biointelect
Benjamin Herz

Senior Analyst and Operations Support

Careers

Biointelect offer exciting and dynamic opportunities to work with a diverse range of clients on equally diverse challenges in commercialisation of medicines and biotherapeutics, and associated policy issues.

If you are looking to scale your career growth and play an integral role in advancing healthcare for all, why not join one of Australia’s leading biotech consulting firms.

Explore Opportunities
Jennifer Herz, Co-founder of Biointelect

Jennifer Herz

Co-founder & Strategic Advisor

Jennifer Herz, GAICD, co-founded Biointelect in 2011, offering end-to-end strategic commercialisation services to the biopharmaceutical sector. She has over 30 years of experience in commercial, business development and scientific affairs within the biopharmaceutical industry across Australia, New Zealand and Europe. 

Early in her career, she played a pivotal role at Sanofi Pasteur, establishing and managing the company as a major provider of vaccines in Australasia. She was also the founding Chair of the Medicines Australia Vaccine Industry Group and has extensive Board experience, serving for publicly listed private and not-for-profit organisations, including Medicines Australia. She then took on a regional policy and market access role where she was engaged in various international industry association working groups, fostering relationships with health authorities, the EU institutions, and the WHO. 

More recently, Jennifer took on Director roles in two NASDAQ-listed US-based biotech company subsidiaries in Australia, became a member of influential committees like the NHMRC’s Health Research Impact Committee, the NSW Innovation and Productivity Council, and the Australian AMR Network’s steering committee.

During her time leading Biointelect, she has overseen more than 450 projects, providing rich and diverse experience in the complexity of life science product development and integrated commercial strategy. This experience includes successful FDA, EMA and TGA approvals, global launches, and product and company failures, providing valuable learning opportunities. 

 Jennifer has an extensive local and international network of industry, policy, scientific and clinical experts across many therapeutic areas and healthcare sectors, along with global experience in multiple new product launches and start-ups at all stages of development. 

Karl Herz, Co-founder of Biointelect

Karl Herz

Co-founder

Karl Herz is one of the co-founders of Biointelect. He has over 25 years of experience in the pharmaceutical industry, holding a Bachelor’s degree in Biomedicine, specialiasing in Biochemistry and Microbiology, and a Post-Graduate Certificate in Marketing from the University of Technology Sydney. His career spans laboratory work and senior management. 

Karl has honed extensive commercial expertise working with numerous multinational pharmaceutical companies, including GSK, Servier and Sanofi. During his career, he gained significant experience collaborating with stakeholders such as hospitals, healthcare specialists, primary care and pharmacy channels within a diverse range of therapeutic areas ranging from over-the-counter, generics, and prescription medicines.  

In his current capacity, Karl serves as a board member of Biointelect and holds the position of Managing Director at Biocelect, a company dedicated to the distribution of pharmaceutical and biotechnology products on behalf of firms seeking to launch their products in the Asia Pacific Region.  

Leah Goodman, Biointelect's Chief Executive Officer

Leah Goodman

Chief Executive Officer

Leah Goodman has over 20 years of Multinational Pharmaceutical leadership experience, including Managing Director ANZ roles with Bristol-Myers Squibb and Merck Healthcare, and more than a decade with Sanofi across commercial Regional responsibilities including Japan, South Korea, Australia/New Zealand as Vice President based in Tokyo, and South East Asian countries as Managing Director based in Malaysia.

 

Through her Industry Association Board leadership across Asia and Australia Leah has played a significant role in market shaping for equitable healthcare access, including as a member of the Board of Medicines Australia from October 2019 to December 2021. Her experience spans innovative biotechnologies across diverse therapeutic areas, as well as across government investment into infrastructure with cell and gene therapy manufacturing in RNA and Viral vectors. Leah has a Bachelor of Science and Masters of Commerce from UNSW, is an AICD Graduate, and has certification in advanced GMP manufacturing.

 

Today, she continues to be active in the Australian LifeScience network, participating as a member of the AusBiotech NSW Leadership Committee, the BioNSW subcommittee on commercialisation, and as a member of the Catalyst Cell and Gene Therapy Policy and Advocacy Working group. She is a member of the Australian Chief Executive Women Network and is an actively passionate advocate for diversity.

Dr Patricia Vietheer

Senior Director, R&D Strategy & Planning

Dr. Patricia Vietheer has 20 years of experience in the life sciences industry, specialising in the commercialisation of early-stage technologies and product development. She holds a Ph.D. in Microbiology from Monash University and an MBA majoring in Strategy and Planning from Deakin University. 

Throughout her career, Patricia has worked in diverse sectors, including academia, start-up companies, medtech and biotech, across various disease areas and technology types. She also contributed to numerous granted patents, co-authored multiple scientific publications in peer-reviewed journals, presented at numerous national and international conferences, and earned multiple awards, including the NHMRC Dora Lush BioMedical Award, the Australian Defence Force Prince of Wales Award and the Australian Centre for HIV & Hepatitis Virology Young Investigator’s Award.  

Patricia joined Biointelect in 2019, initially leading the R&D Strategy and Planning team. She is now the Senior Director of Strategy, Marketing and Business Development, leading numerous projects in commercialisation strategy, business case development, planning and execution for key clients, including universities, research institutes, government, start-ups, and pharmaceutical, biotech and medtech companies.  

Brian Gilmartin

Director, Regulatory Affairs

Brian Gilmartin has more than 20 years of international experience in the pharmaceutical industry, having worked across Europe, Asia Pacific, Japan and ANZ. He holds a Master of Science in Bioinformatics and a Bachelor of Science (Honours) in Biological Sciences with a Biotechnology specialty.

Earlier in his career, Brian began as a Bioinformatics computer associate working in drug discovery startups before joining a genome project at the University of Cambridge, Institute of Medical Research. Brian crossed over to the pharmaceutical industry in 2004, focusing on regulatory affairs and gaining substantial experience in new product development, manufacturing and clinical with leading commercialisation consulting companies.

During the past decade, Brian has channeled his broad exposure across the pharmaceutical industry into building out a pharmaceutical products and services company across the JAPAC region supporting clinical trial supply, early access programs, unlicensed supply and the commercialisation of lifesaving medicines to address the unmet medical needs of patients.

Brian joined Biointelect and Biocelect in November 2023.

Katrina Lapham

Director, Strategic Market Access & Policy

Katrina Lapham has more than 15 years of international experience in the healthcare and biopharmaceutical industries across Australia, the United States, the United Kingdom and emerging markets. She holds a Master of Science from the London School of Economics, Policy and Management and a Bachelor’s in Economics (Honours) from the University of Western Australia. Her professional portfolio encompasses policy design and evaluation, funding model analysis, and program evaluation. 

Early in her career, Katrina began as a health policy analyst within the Australia Government Treasury and then joined Deloitte as an Associate Director of Health Economics and Social Policy. Later, she relocated to London, where she led market access strategy, policy and real-world evidence-generation projects. She has had broad exposure across the healthcare sector, collaborating with government bodies, industry , patient advocacy groups and other non-profit organisations. In recent years, she directed two multi-country real-world evidence studies focusing on neurodegenerative diseases.  

Katrina joined Biointelect in 2020 as the Director of Strategic Market Access and Policy, leading numerous projects with biopharmaceutical companies, government agencies and patient organisations. Her expertise contributes to the development of actionable strategies and support in areas such as reimbursement submissions, policy white papers, stakeholder engagement, internal workshops and reports.  

Nicola Richards

Director, Strategic Market Access & Policy

Nicola has over 30 years’ experience pharmaceutical experience in the full range of commercial roles including sales, marketing and business development. She had been in Executive leadership roles including Market access, Public Affairs, Policy and Commercial operations. She has a Bachelor of Science degree.

Nicola has been heavily involved in health care industry work, including roles an industry representative on the Medicine Australia Strategic Advisory Council, Australian Medicine Working Group (AMWG) sub committee and chair/member of various Medicine Australia working groups relating the Strategic agreements and other relevant industry issues. She is also passionate about contributing to consumer committees for NSW Health including eHealth and SDPR

Nicola joined Biointelect in April 2025.

Jacqui Wade

Director, Clinical Affairs & Director Services

Jacqui Wade is a senior life sciences leader with more than 30 years of experience across the pharmaceutical, biotechnology and clinical research sectors. Holding a Bachelor of Science with majors in Pharmacology and Physiology, she has built deep expertise spanning clinical development, product commercialisation and strategic program leadership across multiple therapeutic areas, including oncology, neuroscience, HIV, immunology and infectious diseases.

Jacqui’s early clinical career included being part of the establishment of a Phase I clinical trial unit in Adelaide, and leading Phase II–IV development programs at Janssen, along with contributing to global medical affairs initiatives during an international assignment in Canada. She later held commercial leader roles, successfully managing the PBS launches of innovative therapies in prostate cancer and chronic lymphocytic leukaemia and guiding cross‑functional teams through complex, high‑impact product introductions.

Before joining Biointelect, Jacqui served as a Project Director within a CRO, supporting small to medium‑sized biotechs with early‑phase clinical strategy and execution, and held a Director role in a biotechnology company, strengthening her understanding of early‑stage organisational needs.

Since joining Biointelect in 2022, Jacqui has led the growth and delivery of the company’s full‑service CRO capabilities, overseeing early‑phase clinical strategy, study execution and cross‑functional operational leadership. She also oversees Director Services, supporting biotechs entering the Australian market through resident directorship, governance and corporate secretarial support, financial and tax compliance, and access to Australia’s R&D Tax Incentive.

With a career grounded in both scientific and commercial disciplines, Jacqui is recognised for her ability to integrate clinical, regulatory and commercial considerations into clear, actionable development strategies. She partners closely with clients to build capability, reduce risk and accelerate the path from innovation to impact.

Dr Danijela Mirosa

Senior Consultant Manager, Business Development Head

Dr Danijela Mirosa brings 20 years of experience spanning biotech, biopharma, and healthcare innovation. As Senior Consultant Manager, Business Development Head, she leads Biointelect’s Business Development function (including Business Insights and Marketing) while providing strategic guidance to clients across the life sciences sector. Her unique expertise bridges scientific discovery, commercial strategy, and business excellence, leveraging strategic data analytics to drive growth and effectiveness.

Her career spans from biotech R&D at CSL Limited to Country Leadership Team positions in multinational biopharma companies, including roles as Oncology Franchise Director and Head of Strategy & Patient Services, where she successfully led commercialisation strategies and product launches across multiple therapeutic areas.

She holds a PhD in Biomedicine and MBA from the University of Melbourne, with certifications in Agile methodologies, health economics and digital marketing strategy (INSEAD).

Dani joined Biointelect in April 2024.

Dr Gary O'Brien

Senior Health Economics and Market Access Manager

Dr. Gary O’Brien has more than 10 years of international experience in the healthcare and biopharmaceutical industries across Ireland, the United Kingdom, Western Europe and Australia. He holds a PhD from University College Cork, Ireland in Pharmacoeconomics and Health Policy, a Master of Pharmacy from the Royal College of Surgeons, Ireland, a Postgraduate Certificate in Innovation, Commercialisation and Entrepreneurship from University College Cork, Ireland and a Bachelors of Pharmacy from University College Cork, Ireland. He has also completed additional Health Economics training in the University of York, England and Oxford University, England.

His professional portfolio encompasses policy design and evaluation, cost-effectiveness analysis, drug reimbursement, national payment systems, and clinical trials. Early in his career, Gary began as a Community and Clinical Trials Pharmacist working in the Irish and European Healthcare landscapes before returning to academia. During the time spent in academia completing his PhD in Pharmacoeconomics and Health Policy, Gary worked as Clinical Pharmacy lecturer publishing over 30 publications. After this time, Gary worked in various pharmaceutical industry roles such as Clinical Trial Associate for Eli Lilly, Health Economist for GSK, and Market Access and Government Affairs Manager for AbbVie.

He has had broad exposure across the healthcare sector, collaborating with government bodies, industry, patient advocacy groups and other non-profit organisations. In recent years, he has achieved numerous pharmaceutical product reimbursements in the Oncology, Infectious Disease and Neuroscience spaces.

Gary joined Biointelect in 2025 as the Senior Health Economics and Market Access Manager, leading numerous projects with biopharmaceutical companies, government agencies and patient organisations. His expertise contributes to the development of actionable strategies and support in areas such as reimbursement submissions, policy white papers, stakeholder engagement, internal workshops and reports.

Sophie Goddard

Manager Consultant

Sophie holds a Bachelor of Commerce with majors in Marketing and International Business and a Bachelor of Advanced Studies in Business from the University of Sydney. 

Prior to joining Biointelect, Sophie began her career in KPMG’s Management Consulting division in the Policy, Economics, and Public Impact team. In this role, she supported a diverse range of clients within the Health and Aged Care sector. Sophie gained valuable experience during her studies by working with Accenture in the United Kingdom as an external student consultant. Here, she collaborated with an interdisciplinary team to design digital solutions for the UK National Health Service, addressing key health challenges faced by elderly populations. 

Sophie joined Biointelect in 2022 in the Strategic Market Access and Policy team. In her role at Biointelect, Sophie supports clients in navigating policy, developing strategies, and driving implementation. Her experience with Biointelect has further enriched her understanding of the healthcare and biopharmaceutical sector, including its operational environment, workflow, and strategic priorities. Sophie has contributed to the development of business cases, conducted commercial assessments, crafted strategic plans, designed operational models, evaluated programs, engaged stakeholders, and managed projects. Her work has spanned various therapeutic areas, including genomics and regenerative medicine. 

Jacky Arkell

Senior Consultant – Regulatory Affairs

Dr Jacky Arkell brings over 20 years of Regulatory experience within the pharmaceutical and medical technology industry. She holds a PhD from the University of Sydney, starting her career in medical research, in the areas of endothelial cell and angiogenesis research, rheumatoid arthritis and in-vitro reproduction at Royal North Shore Hospital, Sydney.

Over 10 years at Alexion Pharmaceuticals, a rare disease company acquired by AstraZeneca in 2021, Jacky successfully registered and launched multiple orphan drugs in Australia and Asia, and held various leadership positions across global, Australia and Asia Pacific teams. Therapeutic areas included rare haematological disorders and genetic metabolic disease and regulatory support included implementing patient registries and utilising accelerated pathways.

Jacky spent another decade at Roche Pharmaceuticals where she utilised her diagnostic registration experience to support various personalised medicine and pan-tumour therapies. She managed the HER2 medicine portfolio, registering the first antibody drug conjugate in Australia for HER2 breast cancer.  Earlier in her career, Jacky worked at Alcon Laboratories, maintaining OTC and prescription eye drops registrations and supporting the ophthalmology surgical business.

She brings cross functional expertise across Pharmacovigilance, Medical Compliance and Quality Assurance/Supply Chain and deep system experience including information management systems, regulatory data analytics and quality management systems.

Jacky joined Biointelect in December 2024.

Dr Clare Fedele

Senior Consultant R&D Strategy and Planning

Dr Clare Fedele brings over 20 years of experience in the life sciences sector, spanning academic research, science/health communication, research project management and biopharmaceutical R&D.

She holds a PhD in Biochemistry and Molecular Biology from Monash University, specialising in oncology. Clare held the position of Senior Research Scientist in Translational Research at CSL, supporting progression of assets through the R&D pipeline. While at CSL Clare specialised in the cardiovascular and renal therapeutic area, helping to grow CSL’s Research portfolio. Prior to this she held senior research roles at The University of Melbourne Centre for Cancer Research and Peter MacCallum Cancer Centre. Clare has co-authored more than 25 peer-reviewed scientific publications and contributed to multiple successful competitive grants.

She has been the recipient of multiple awards, including postdoctoral fellowships from NHMRC and Victorian Cancer Agency, and was a Science and Technology Australia Superstar of STEM. Clare joined Biointelect in 2025 as part of the R&D Strategy and Planning team. Clare applies her extensive experience in life sciences research to provide strategic support to clients to drive progression of research into commercial success.

Clare joined Biointelect in April 2025.

Lena Miloradovic

Strategic Project Manager

Lena Miloradovic brings over 30 years of project management and operational experience in the biotech industry. She holds a Bachelor of Biological Science from La Trobe University and is a certified Project Management Professional (PMP)® by the Project Management Institute USA. Her extensive expertise encompasses managing complex projects in vaccine development and establishing efficient quality management systems. 

Early in her career, Lena joined CSL Research and Development (R&D) to manage the development of vaccines. Her roles included working with small biotech companies in R&D product development, program management, and the establishment of quality management systems. Her operational experience, covering manufacturing and quality aspects, provided a solid foundation for managing late-stage R&D vaccine development projects. This included overseeing the internationalisation of BioCSL influenza vaccines in the United States and Europe and leading product development studies and clinical trials for early-stage vaccines.  

Lena joined Biointelect in 2021 as the Project Manager for the Novavax COVID-19 Vaccine. In this pivotal role, she provided support to Biocelect as the local sponsor, collaborating closely with cross-functional teams and international and local stakeholders to facilitate the introduction of this vaccine to the Australian and New Zealand populations during the COVID-19 pandemic. She also provided strategic project management support to the University of Melbourne and Doherty Institute collaboration on a COVID-19 vaccine candidate for Phase 1 clinical study. 

Kara Gooley

Senior Project Manager – Clinical Affairs

Kara brings over 23 years of clinical research experience in the pharmaceutical and clinical research organisation sector. She holds a Master of Medical Science, Drug Development from the UNSW.

Kara has experience leading teams across all phases of drug development (I – IV), mostly recently leading a department of 60 project management professionals delivering over 160 clinical trials. Kara has a passion for developing high performing teams who provide high quality project delivery services for biotech customers.

Kara joined Biointelect in August 2024, to work with Jacqui Wade, building full service clinical trial capabilities

Nathan Fox

Health Economics Lead

Nathan Fox has almost ten years of experience consulting in pharmaceuticals, medical services, and devices across Australia, New Zealand, APAC, and Europe. He holds a Master of Economics and Public Health and a Bachelor of Economics & Commerce. His expertise spans health technology assessment, reimbursement systems and processes, policy, and economics. 

Throughout his career, he has successfully developed submissions for global pharmaceutical companies to the Pharmaceutical Benefits Advisory Committee (PBAC), the Pharmaceutical Benefits Schedule (PBS) in Australia and New Zealand’s Pharmaceutical Management Agency (PHARMAC), gaining expertise in product positioning and economic and financial modelling. Nathan also worked at PHARMAC reviewing the therapeutic positioning and health economic and financial implications of potential funding options for medicines, vaccines, and rare diseases.  During this time, Nathan has contributed to more than 50 HTA evaluations across a diverse range of therapeutic and disease areas.

Nathan joined Biointelect in 2021 as a Consultant in the Strategic Market Access & Policy team. His contributions have included advising vaccine and rare disease companies on funding submissions and negotiations, authoring published position papers for Medicines Australia, and academic articles for the industry. Additionally, Nathan has delivered a commercialisation valuation cost-benefit analysis submission to the state government and guided early-stage product developers and clinical trial industry operators on product value propositions and economic impact assessments for technology precincts.

Dr Alysha Elliott

Project Manager – Clinical Affairs

Dr. Alysha Elliott has over 15 years of experience in the Life Sciences industry. She holds a Ph.D. in Molecular Bioscience from the University of Queensland, focusing on drug discovery. Her expertise spans molecular biology, microbiology, biochemistry and antimicrobial drug development.  

Throughout her career, Alysha managed preclinical evaluations of novel antimicrobials, led a crowd-sourcing screening program with over 330 participant groups, and conducted contract research for Biotech companies. She received the prestigious Endeavour Executive Fellowship in 2018, gaining commercialisation experience at Cambridge Enterprise (UK) and the biotech start-up Inflazome Pty Ltd, later acquired by Roche in 2020. Alysha’s work has resulted in over 70 peer-reviewed research articles and numerous awards, including the Antibiotic Guardian award for Research UK, finalist recognition in The Australian Innovation Challenge, Australian Museum Eureka Prizes, and the AusBiotech-GlaxoSmithKline Student Excellence Award in Translational Research. Her interdisciplinary infectious disease research attracted funding from globally recognized bodies such as the Wellcome Trust (UK), the National Institutes of Health (NIH, USA), and CARB-X (Combating Antimicrobial Resistant Bacteria Biopharmaceutical Accelerator), supported by BARDA, GAMRIF, Wellcome, the Bill and Melinda Gates Foundation, among others. 

Alysha joined Biointelect in 2023 as a Project Manager, providing expertise in infectious diseases and facilitating the development of innovative therapies and diagnostics. 

Dr Audrey Rollin

Consultant

Dr. Audrey Rollin holds a PhD in Health & Biomedical Informatics from the University of Sydney, specialising in empowering healthcare professionals to enhance care for Australians treated for Melanoma using technology. She also completed a Master’s in International Marketing and Communications and a Bachelor’s in Clinical Psychology from Paris and Joensuu, Finland, providing a holistic approach to healthcare challenges. She has experience in the digital health and medical research sectors.

Throughout her career, Audrey worked across various roles in marketing, research, project management, and product development in government and multinational companies in Australia and overseas. She led improvements in a national digital mental health therapeutics platform at St Vincent Hospital Sydney. Prior to that, Audrey contributed her expertise to the Commonwealth Scientific and Industrial Research Organisation (CSIRO), where she supported the business development of the Minimizing Antimicrobial Resistance Mission. Her responsibilities included establishing strategic priorities, developing a measurement and evaluation framework, and creating pathways to impact in close collaboration with key stakeholders from the five sectors of One Health. Additionally, she managed strategic research projects aimed at laying the groundwork for the Mission’s objectives. 

Audrey joined Biointelect in 2023 as a Senior Associate, where her focus will be on digital health and marketing.   

Nicole Murray

Senior Associate

Nicole brings over 4 years of Market Access, HEOR and Business Excellence. She holds a Masters degree in Health Economics and a Bachelor Honours degree in Human Nutrition.

Prior to joining Biointelect, Nicole worked at Novartis Australia, where she drove business excellence and execution. In this role, she supported an Australia‑wide project focused on maximising therapeutic assets through the use of artificial intelligence. Nicole previously served as a Market Access Manager in rare diseases at Sanofi Aventis, where she successfully led the economic analysis and reimbursement submission for the LSDP.

Nicole’s pharmaceutical career began in a global role with Novartis Ireland as a HEOR Graduate, where she later progressed to an Analyst position, supporting multiple therapeutic areas across product launches and early access programmes.

Nicole joined Biointelect in 2026 as a Senior Associate in Commercialisation and is currently supporting commerclisation, market access and policy projects across biopharmaceutical companies, government agencies, and patient organisations.

Vincent Victory

Senior Associate

Vincent holds a Master of Biotechnology and a Bachelor of Biomedicine with a major in Pathology from the University of Melbourne.

With over 3 years of consulting experience in the life sciences industry, Vincent specialises in commercialisation, market access, and stakeholder analysis for pharmaceutical and MedTech clients. In his previous role at Commercial Eyes, Vincent led a range of successful projects spanning major Australian reimbursement submissions (PBAC, MSAC, and the Prescribed List), pricing strategy and negotiation, competitive intelligence, financial modelling, and go-to-market plans for both early and late-stage clients. Vincent has delivered projects across a diverse range of therapeutic areas and multiple geographies, including Australia, New Zealand, Singapore, and Japan.

 

Vincent joined Biointelect in February 2026 in the Market Access, Policy and Commercialisation team. In his role, he supports clients in navigating complex treatment and payer landscapes and in developing robust commercialisation strategies. He has a particular interest in both traditional and emerging reimbursement pathways, helping clients identify innovative routes to market. He is particularly passionate about bridging scientific innovation with sustainable patient access.

 

Athiya Azeem

Associate

Athiya brings experience across scientific research, product development, and early‑stage commercialisation. She holds a PhD from the University of Sydney, specializing in the fluid mechanics of dry powder inhalers for improved pulmonary drug delivery.

Her recent work includes leading the commercialisation efforts for a university spin‑out, where she secured pre‑seed funding, established partnerships for product trials, and engaged potential licensees and collaborators.

Athiya joined Biointelect in 2026 as an Associate contributing to strategic analysis and commercial support across Biointelect’s portfolio of health and biotech projects.   

Jasmine Perera

Business Insights Associate

Jasmine brings over two years of experience in the life sciences industry, with expertise in market research, stakeholder engagement, and market access. She holds a Master of Biotechnology from the University of Melbourne and a Bachelor of Science, majoring in developmental biology.

In her previous role at Commercial Eyes, Jasmine has led both qualitative and quantitative research, competitor landscape assessments, and go-to-market strategies for both global and early-stage clients across the pharmaceutical and medical device sectors. She also contributed to regulatory and reimbursement submissions to the TGA and PBAC.

Jasmine joined Biointelect in July 2025, where she contributes to strategic business growth by identifying and engaging with potential leads and opportunities. She supports cross-functional teams in connecting with prospective clients and strengthening commercial strategies through targeted, data-informed insights.

Nicki Sidwell

Executive Officer and Marketing Associate

Nicki Sidwell holds a Certificate 4 in Business through Macquarie Business College and completed a Scrum Master training in Agile Project Management through Epic Consulting Services. 

Previously, Nicki worked at Novartis Oncology for 18 years. During her time there, Nicki provided marketing and sales support across the key marketed Oncology brands. Event management of Novartis Sales Conferences and Scientific Meetings. Her recent position was the Customer Operation Manager for the logistical management of Novartis’ CAR-T therapy in Australia.  

Nicki joined Biointelect in 2023 as a Project Officer, supporting the consulting teams and their clients to achieve the best results for them.

She transitioned into the role of Marketing Associate in April 2024, where she plays a key role in driving marketing initiatives, crafting compelling campaigns, and enhancing brand visibility. Her focus is on optimizing digital marketing efforts, and engaging target audiences to elevate the company’s presence in the marketplace. 

She moved into the role of Executive Officer in December 2024, where she plays a pivotal role in supporting the leadership team, coordinating events, and overseeing office management to ensure seamless operations.

Marcelo Salvatte Pinheiro

Quality Lead

Marcelo holds a B.Sc in Biomedical Sciences from the Federal University of Mato Grosso, Brazil, where he contributed to the Laboratory of System Physiology and Reproductive Toxicology. He also completed an internship at the Molecular Genetics Laboratory at the University of Nebraska Omaha, USA.

Throughout his career, Marcelo has managed complex projects across diverse therapeutic areas in the clinical trials industry, from first-in-human to post-marketing trials. In his recent role as a Clinical Quality and Training Associate, he optimized processes and lead teams through successful audits.

Marcelo joined Biointelect in 2024, bringing his passion and expertise in quality and compliance. He focuses on quality management systems (QMS) and collaborates with various functional areas to deliver high-quality results in a dynamic environment

Senior Analyst and Operations Support professional at Biointelect

Benjamin Herz

Senior Analyst and Operations Support

Benjamin Herz is a Senior Analyst and Operations Support professional at Biointelect, specialising in financial modelling, forecasting, and data-driven decision support for life sciences projects. He plays a key role in developing financial reports, maintaining Salesforce dashboards, and supporting leadership with insights that guide strategic planning, performance tracking, and resource allocation. Benjamin also contributes to financial policy development, audit preparation, and profitability analysis across Biointelect core business and the Biointelect Venturer Project.

He holds a Bachelor of Economics from Macquarie University and postgraduate training in finance and valuation from Vrije University Amsterdam. Outside of work, Benjamin is an active sports enthusiast who enjoys basketball, surfing, and travel.

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.